TSHA•benzinga•
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?
Summary
Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 29, 2025 by benzinga